Friday 6 November 2026 Export ACAD’s income statement to Excel — free account

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.

Revenue: +22.9%
EPS: −27.9%
Free cash flow: +141.2%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

21.19 0.05 −0.24%

Follow ACAD

Alert me

Market cap: $3.7B
P/E: 10.0×
Fwd P/E: 33.4×
Dividend yield: —
F-score: 6/9
Altman Z: 7.90
Beneish M: −0.89
Dividend safety: n/a

Overview

ACADIA Pharmaceuticals Inc. (ACAD) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, ACADIA Pharmaceuticals Inc. (ACAD) trades at a P/E ratio of 10.0×. Over the past ten years it has ranged from 0.0× (June 2024) to 106× (July 2024); the current reading is higher than 84% of that period. That is in line with the Biotechnology industry median of 10.3× and below the Healthcare sector median of 25.2×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ACAD/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="ACADIA Pharmaceuticals Inc. P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ACAD/metrics/pe-ratio">ACADIA Pharmaceuticals Inc. (ACAD) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	11.5×	(14.67%)
FY2024	13.5×	—
FY2023	0.0×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	0.0×	—
FY2018	0.0×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	P/E ratio	Change
Sep 2026	9.5×	(15.87%)
Jun 2026	11.2×	12.65%
Mar 2026	10.0×	(13.30%)
Dec 2025	11.5×	(15.84%)
43 more quarters	Free account

Against its own ten years

Low 0.0× High 106×

Ten-year median 0.0×

Current reading's percentile 84

Company	P/E ratio
VKTX Viking Therapeutics, Inc. compare	n/m
TNGX Tango Therapeutics, Inc. compare	n/m
PBLS Parabilis Medicines, Inc. compare	n/m
IRON Disc Medicine, Inc. compare	n/m
IOVA Iovance Biotherapeutics, Inc. compare	n/m
RLAY Relay Therapeutics, Inc. compare	n/m
DYN Dyne Therapeutics, Inc. compare	n/m
XENE Xenon Pharmaceuticals Inc. compare	n/m
ACAD ACADIA Pharmaceuticals Inc.	10.0×
Biotechnology industry median	10.3×
Healthcare sector median	25.2×
Market median	17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

ACADIA Pharmaceuticals Inc. (ACAD) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on ACAD

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on ACAD

Stockrow Weekly